Nom du produit:Benzo[d]thiazole-6-sulfonyl chloride

IUPAC Name:1,3-benzothiazole-6-sulfonyl chloride

CAS:181124-40-3
Formule moléculaire:C7H4ClNO2S2
Pureté:97%
Numéro de catalogue:CM158498
Poids moléculaire:233.68

Unité d'emballage Stock disponible Prix($) Quantité
CM158498-5g in stock ǟǎǎ
CM158498-10g in stock ǟƚŌ
CM158498-25g in stock ħǟƚ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:181124-40-3
Formule moléculaire:C7H4ClNO2S2
Point de fusion:-
Code SMILES:O=S(C1=CC=C2N=CSC2=C1)(Cl)=O
Densité:
Numéro de catalogue:CM158498
Poids moléculaire:233.68
Point d'ébullition:376.9°C at 760 mmHg
N° Mdl:
Stockage:Store in freezer, under -20°C.

Category Infos

Benzothiazoles
Benzothiazoles are aromatic heterocyclic compounds with the chemical formula C7H5NS. Benzothiazoles and their derivatives are a very important class of heterocyclic compounds that are ubiquitous in nature and are mainly used in medicine, agriculture and industry. In medicine, benzothiazole derivatives are a kind of very important pharmaceutical intermediates with good pharmacological and biological activities. It can be used as a fungicide, anti-tuberculosis drug, anti-malarial, anti-convulsant, insecticide, sedative and anti-inflammatory drug, and can also be used to treat diabetes and has anti-cancer effects.

Column Infos

Lanifibranor
Recently, Inventiva announced positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH/NASH and poorly controlled Type 2 Diabetes (T2D). The study achieved the primary efficacy endpoint. Lanifibranor is an orally-available small molecule pan PPAR agonist with a -wellbalanced- activation of PPARα and PPARδ, and a partial activation of PPARγ. Lanifibranor acts to induce anti fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body.

Related Products